Evaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-M?llerian hormone and histological analysis in a rat model using cisplatin

Introduction: The aim of this prospective trial was to evaluate the ovarian reserve with anti-Mullerian hormone (AMH), which is the best predictor of ovarian reserve, and perform histological analysis after exposure to cisplatin with a GnRH agonist or antagonist.Material and methods: Twenty-four Wistar albino rats were randomly divided into three groups, each consisting of eight rats. In the GnRH agonist group (group 1), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg triptorelin. In the GnRH antagonist group (group 2), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg cetrorelix. In the control group (group 3), rats received 50 mg/m2 cisplatin. Ovarian reserve was assessed by AMH and histology.Results: Primary follicle counts were higher in group 2 (4.50 +/- 1.47 vs. 3.50 +/- 1.70 vs. 3.00 +/- 3.54) and secondary follicle counts were higher in group 1 (2.96 +/- 1.11 vs. 1.74 +/- 1.03 vs. 1.37 +/- 3.11). Numbers of tertiary follicles were higher both in groups 1 and 2 than the control group (1.36 +/- 0.83 vs. 0.84 +/- 0.99 vs. 0.50 +/- 0.75). The total follicle count of the study groups were signifi-cantly higher compared with the control group (14.32 +/- 5.96 vs. 12.48 +/- 4.12 vs. 10.63 +/- 6.80). AMH was significantly higher in groups 1 and 2 compared with the control group (18.56 +/- 25.33 vs. 16.48 +/- 24.66 vs. 9.37 +/- 26.54).Conclusions: This is the first prospective randomized controlled study show-ing the protective effects of GnRH agonist and antagonist on ovarian reserve after cisplatin exposure in an animal model.

Automated summary

This study evaluated ovarian reserve using anti-Mullerian hormone (AMH) as the best predictor, and conducted histological analysis after cisplatin exposure with a GnRH agonist or antagonist. The results showed that ovarian reserve and AMH levels were significantly increased in the GnRH agonist and antagonist groups compared to the control group. This is the first prospective randomized controlled study to demonstrate the protective effects of GnRH agonist and antagonist on ovarian reserve after cisplatin exposure in an animal model.